‘Belimumab has fulfilled the principal endpoint in both of its pivotal Stage 3 trials. Earlier this month, we and GSK submitted advertising applications for belimumab in the United Europe and States. We anticipate the thought and conclusions of regulatory authorities now.’ Carlo Russo, M.D., Senior Vice President, Biopharm Advancement, GSK, stated, ‘With both of the pivotal Stage 3 trials completed successfully, the results presented at main scientific meetings and regulatory applications today under review, we very much hope that we will be able to deliver a fresh option for the treatment of systemic lupus.’ Belimumab can be an investigational drug and the initial in a new class of medicines called BLyS-specific inhibitors. It really is being produced by HGS and GSK under a co-advancement and commercialization contract entered into in 2006.Unless we really focus on those long-term problems and get yourself a high way of measuring agreement, today and tomorrow we are not going to make the proper decisions, Feachem stated. Related StoriesNew study discovers high prevalence of HIV among pregnant refugee ladies in OntarioRutgers College of Nursing takes lead in $6 million nationwide effort to prevent new HIV infectionsSafe, effective douche-centered rectal microbicide can prevent HIV in gay menHe also noted that decisions would need to be made soon about the part of vaginal microbicides – – gels, movies and sponges that could help prevent the sexual transmitting of HIV and other infections – – male circumcision and vaccines in the fight HIV/AIDS worldwide .